preclinics Italia, along with its partners Diatheva and Toscana Life Sciences, has secured funding for the innovative PISAMUNAB project, aimed at revolutionizing the landscape of antibody-based diagnostic and therapeutic solutions. The project, titled Integrated platform for the development of human monoclonal antibodies and nanobodies for biomedical applications, seeks to accelerate the discovery of next-generation biomedical solutions, with a focus on monoclonal antibodies and nanobodies for advanced biomedical applications.
The project was selected under the VITALITY Ecosystem initiative, supported by Italy’s National Recovery and Resilience Plan (PNRR) and NextGenerationEU. This significant recognition highlights the project’s high scientific and technological impact, which will run from July 2024 to June 2025. The initiative aims to strengthen biomedical innovation by supporting advanced research in the biotechnology sector.
The consortium, which includes preclinics Italia, Diatheva – a biotech company specializing in innovative diagnostics and biologic therapeutics – and Toscana Life Sciences, a foundation promoting biotech innovation through research and enterprise incubation, will work on developing an advanced platform for the discovery of single-domain and conventional antibodies. The goal is to drive healthcare innovation by improving diagnostic and therapeutic solutions to meet the needs of modern medicine.
preclinics Italia is proud to contribute to this initiative, which underscores the commitment of the consortium partners to pioneering biomedical research and driving innovation in the biotechnology sector.
For more information, contact: [italia@preclinics.com]
